Next-generation tumor-activated biologics platform enabling systemic delivery that activates only in the tumor microenvironment for safer, more durable anti-tumor responses. Lead Fc-enhanced, high-affinity CD47 blocker shows curative activity without historical safety/exposure limitations; platform applicable to cytokines, TCEs, and ADCs to support a diversified oncology pipeline.